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Interaction among COX-2, P2Y1 and GPIIIa
gene variants is associated with aspirin
resistance and early neurological
deterioration in Chinese stroke patients
Xingyang Yi1*, Chun Wang1, Qiang Zhou2* and Jing Lin2
Abstract
Background: The effect of genetic variants on aspirin resistance (AR) remains controversial. We sought to assess
the association of genetic variants with AR and early clinical outcomes in patients with acute ischemic stroke (IS).
Methods: A total of 850 acute IS patients were consecutively enrolled. Platelet aggregation was measured before
and after a 7–10 day aspirin treatment. The sequences of 14 variants of COX-1, COX-2, GPIb, GPIIIa, P2Y1 and P2Y12
were determined using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Gene-gene
interactions were analyzed using generalized multifactor dimensionality reduction (GMDR). The primary outcome
was early neurological deterioration (END) within 10 days of admission. The secondary outcome was a composite
of early recurrent ischemic stroke (ERIS), myocardial infarction (MI) and death within 10 days of admission.
Results: 175 (20.6%) patients were AR, 45 (5.3%) were aspirin semi-resistant, 121 (14.2%) developed END, 17 (0.2%)
had ERIS, 2 (0.2%) died, and 6 (0.7%) had MI. Single locus analysis indicated that only rs1371097 was associated with
AR. However, GMDR analysis indicated that the following three sets of gene-gene interactions were significantly
associated with AR: rs20417CC/rs1371097TT/rs2317676GG; rs20417CC/rs1371097TT/rs2317676GG; rs20417CC/
rs1371097CT/rs2317676AG. END occurred significantly more frequently in patients with AR or high-risk interactive
genotypes. Moreover, AR and high-risk interactive genotypes were independently associated with END.
Conclusion: Sensitivity of IS patients to aspirin and END may be multifactorial and is not significantly associated with a
single gene polymorphism. Combinational analysis may useful for further insight into the genetic risks for AR.
Keywords: Ischemic stroke, Aspirin resistance, Genetic variants, Polymorphism, Early neurological deterioration
Background
Stroke is one of the leading causes of human mortality
and disability [1]. Early neurological deterioration (END)
and recurrent ischemic stroke (ERIS) are common and
are associated with poor prognosis in acute ischemic
stroke (IS) patients [2]. Aspirin is routinely used for the
treatment of IS [3], and its use is associated with im-
proved outcomes [2, 4]. However, recent studies have
shown that aspirin resistance (AR) can lead to the failure
of antiplatelet therapy [5], and is associated with fre-
quent END and ERIS in patients with acute IS [6, 7].
Thus, further identification of risk factors for AR could
improve the treatment of patients at risk of IS, enabling
clinicians to choose more effective treatments.
Aspirin acts by inhibiting platelet cyclooxygenase en-
zymes (COX), preventing generation of thromboxane A2
(TXA2) from arachidonic acid (AA). TXA2 binds to
glycoprotein coupled receptor (GPIIb/IIIa) leading to
phospholipase C activation and platelet aggregation [8].
The platelet membrane receptors P2Y12 and P2Y1 play
a key role in platelet aggregation, thrombosis and
pharmacological targeting of these receptors [9]. Adeno-
sine diphosphate (ADP) amplifies multiple signal
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pathways to activate platelets through autocrine and
paracrine mechanisms, whereas inhibition of P2Y12 re-
ceptors prevents ADP-induced platelet activation [10].
P2Y12 antagonists have been shown to potently inhibit
platelet activation [11]. Therefore, genetic variants of
these signal molecules may contribute to AR.
A number of studies have assessed the association of
AR with single nucleotide polymorphisms (SNPs) in
COX and the above mentioned receptors genes. For ex-
ample, polymorphisms in COX-1, COX-2, GPIIIa, P2Y1,
P2Y12 were reported to contribute to AR [12–17]. How-
ever, other studies, including a previous study published
by this group, did not find aspirin responsiveness to be
associated with these variants in patients with symptom-
atic vascular disease [18–20]. Thus, the role of SNPs in
COX-1, COX-2, GPIb, GPIIIa, P2Y1, P2Y12 in AR re-
mains controversial [21]. These conflicting findings indi-
cate that the contribution of genetic factors to AR may
involve a complex network of mutations. It is possible
that the effects of each locus alone may be too small to
be detected in relatively small patient groups, and only
specific combinations of multiple variants were found to
significantly contribute to AR. Thus, investigating mul-
tiple gene-gene interactions using the generalized multi-
factor dimensionality reduction (GMDR) approach may
be required to accurately characterize the genetic eti-
ology of AR [22, 23]. However, no such studies investi-
gating the effect of gene-gene interactions on AR have
been reported.
We hypothesize that the interaction of particular gen-
etic variants may contribute to AR and END in IS pa-
tients. In this study, we assessed the potential
contribution of fourteen variants in six genes to AR and
END in acute IS patients using GMDR analysis.
Methods
Ethics statement
The study protocol was approved by the Ethics Commit-
tee of the People’s Hospital of Deyang City and the Third
Affiliated Hospital of Wenzhou Medical University.
Written informed consent was obtained from each
patient prior to study enrollment.
Study population
We consecutively enrolled 850 acute IS patients between
August 2010 and August 2014. These patients had their
first IS and were admitted to the participating hospitals
within 72 h of stroke onset. The inclusion criteria were:
1) age ≥ 40 years old; 2) IS was confirmed using brain
magnetic resonance imaging; 3) stroke etiology was
atherothrombotic or small artery disease subtype accord-
ing to a previously described Acute Stroke Treatment
classification system [24]; 4) National Institutes of
Health Stroke Scale (NIHSS) score <15. Exclusion
criteria were: 1) hemorrhagic stroke, or recurrent stroke;
2) aspirin allergy; 3) treatment combined aspirin and
clopidogrel; 4) other etiologies of IS; 5) fever, infection,
un consciousness at admission; 6) administration of
other nonsteroidal anti-inflammatory drugs within
2 week prior to enrollment; 7) using low molecular weight
heparin or heparin within 24 h of enrollment, or thrombo-
lytic treatment; 8) carotid endoartectomy or carotid stent
therapy before or during the follow-up period; 9) platelet
count <100 × 109/L or >450 × 109/L; 10) asthma or severe
cardiovascular, liver, or renal disease.
All patients received standard therapies [3, 25], includ-
ing 200 mg/day aspirin (Bayer Healthcare Company
Ltd., Beijing, China) for 14 days, and 100 mg/day there-
after. Data on various risk factors including age, gender,
current smoking, history of diabetes mellitus and hyper-
tension, were recorded. Fasting blood samples were
tested for triglycerides (TG), total plasma cholesterol
(TC), low-density lipoprotein cholesterol (LDL-C) and
high-density lipoprotein cholesterol (HDL-C).
Platelet aggregation test
Venous blood (3 mL) was drawn from each patient’s
antecubital vein before and after 7–10 days of aspirin
treatment. Platelet aggregation was measured by light
transmittance aggregometry (LTA), as described previ-
ously [2, 5, 18]. A mean aggregation of ≥70% with
10 μM ADP and a mean aggregation of ≥20% with
0.5 mM AA after aspirin intake for 7 to 10 days were de-
fined as AR. A mean aggregation of ≥70% with 10 μM
ADP or a mean aggregation of ≥20% with 0.5 mM AA
was defined as Aspirin semi-resistance (ASR). Patients
with AR and those with ASR were pooled into an AR +
ASR group [5, 18]. Otherwise, patients were considered
aspirin sensitive (AS).
Genotyping
A total of 14 variants in six genes, including COX-1
(rs1236913, rs3842787), COX-2 (rs689466, rs20417),
TXAS1 (rs194149, rs2267679, rs41708), P2Y1 (rs701265,
rs1439010, and rs1371097), P2Y12 (rs16863323,
rs9859538), and GPIIIa (rs2317676, rs11871251) were
selected from the NCBI database (http://www.ncbi.nlm.-
nih.gov/SNP), based on the following criteria: (i) SNPs
that have been assessed in previous studies [12–21]; (ii)
SNPs with minor allele frequency >0.05; (iii) SNPs lead-
ing to amino acid changes.
Whole blood (3 mL) was drawn from the antecubital
vein into a sterile tube containing ethylenediaminetetra-
acetic acid and stored at -80 °C. Genotypes for the 14
variants were assessed using a matrix-assisted laser de-
sorption/ionization time of flight mass spectrometry as
previously described [23]. Each allele was classified ac-
cording to its effect on enzymatic function. For each
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gene, subjects were dichotomized a priori into two
groups based on whether they possessed at least one
mutant allele.
Assessment of clinical outcomes
The clinical outcomes of IS patients were assessed
within the first 10 days of admission. The primary out-
come was END, defined as an increase in NIHSS score
of ≥ 4 points within 10 days of admission, after exclusion
of hemorrhagic transformation of infarct or a new in-
farct in another vascular territory as previously described
[26]. The secondary outcome was a composite of ERIS,
myocardial infarction (MI), and death within 10 days of
admission. ERIS was defined as a sudden and new focal
neurologic deficit of vascular origin lasting at least 24 h,
indicated in a diffusion-weighted image [26]. Death was
defined as all-cause mortality.
Statistical analysis
All statistical analyses were performed using SPSS 16.0
(SPSS Inc., Chicago, IL, USA). Deviation of Hardy-
Weinberg equilibrium for genotype frequencies was ana-
lyzed by χ2-test. Difference in genotype frequencies be-
tween the AR + ASR group and AS group were also
compared using the χ2-test. Baseline and clinical
Table 1 Comparison of clinic characteristics between AS and
ASR or AR patients
Parameter AR + ASR AS P-value
n = 220 n = 630
Age (years) 70.8 ± 12.76 70.01 ± 11.35 0.94
Gender (female, %) 122 (55.45) 285 (45.24) 0.02
Body mass index (kg/m2) 23.85 ± 3.34 23.92 ± 3.32 0.99
Current smoking (n, %) 66 (30.00) 182 (28.89) 0.62
Hypertension (n, %) 157 (71.36) 439 (69.68) 0.89
Diabetes (n, %) 79 (35.91) 112 (17.78) <0.001
Previous MI (n, %) 7 (3.2) 14 (2.2) 0.72
NIHSS score at enrollment 5.91 ± 1.81 5.87 ± 1.86 0.89
TC (mmol/L) 5.32 ± 1.18 5.29 ± 1.76 0.26
TG (mmol/L) 1.80 ± 0.83 1.79 ± 0.90 0.96
HDL-C (mmol/L) 1.32 ± 0.32 1.31 ± 0.33 0.85
LDL-C (mmol/L) 3.13 ± 0.92 2.93 ± 0.86 <0.001
Fasting glucose (mmol/L) 7.21 ± 2.12 6.43 ± 1.86 <0.001
Platelet count (×109/L) 193.01 ± 28.62 196.42 ± 30.46 0.79
Stroke subtype
Atherothrombotic (n, %) 135 (61.36) 384 (60.95) 0.86
Small artery disease (n, %) 85 (38.64) 246 (39.05) 0.86
AR aspirin resistance, ASR aspirin semi-resistance, AS aspirin sensitivity, MI
myocardial infarction, TC total cholesterol, LDL-C low-density lipoprotein
cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, NIHSS
National Institutes of Health Stroke Scale
Table 2 Association of SNPs with responses of aspirin in IS
patients (%)
AR + ASR AS P-value
n = 220 n = 630
COX-1 (rs1236913)
CC 198 (90.0) 567 (90.0) 0.99
CT + TT 22 (10) 63 (10.0)
COX-1 (rs3842787)
CC 171 (77.7) 504 (80.0) 0.76
CT + TT 49 (22.3) 126 (20.0)
COX-2 (rs689466)
AA 63 (28.6) 180 (29.6) 0.89
AG + GG 157 (71.4) 450 (71.4)
COX-2 (rs20417)
GG 142 (64.5) 441 (70.0) 0.26
GC + CC 78 (35.5) 189 (30.0)
TXAS1 (rs194149)
GG 75 (34.1) 190 (30.2) 0.42
AG + AA 145 (65.1) 440 (69.8)
TXAS1 (rs2267679)
TT 178 (80.9) 522 (82.9) 0.53
CC + CT 42 (19.1) 108 (17.1)
TXAS1 (rs41708)
GG 136 (61.8) 373 (59.2) 0.72
TT + GT 84 (38.2) 257 (40.8)
P2Y1 (rs701265)
AA 116 (52.7) 341 (54.1) 0.48
AG + GG 104 (47.3) 289 (45.9)
P2Y1 (rs1439010)
AA 114 (51.8) 346 (54.9) 0.32
AG + GG 106 (48.2) 284 (45.1)
P2Y1 (rs1371097)
CC 106 (48.2) 373 (59.2) 0.01
TT + CT 114 (51.8) 257 (40.8)
P2Y12 (rs16863323)
CC 48 (21.8) 158 (25.1) 0.21
TT + CT 172 (78.2) 472 (74.9)
P2Y12 (rs9859538)
GG 154 (70.0) 472 (74.9) 0.16
AG + AA 66 (30.0) 158 (25.1)
GPIIIa (rs2317676)
AA 132 (60.0) 404 (64.1) 0.24
AG + GG 88 (40.0) 64 (35.9)
GPIIIa (rs11871251)
AA 77 (35.0) 190 (30.2) 0.51
AG + GG 143 (65.0) 440 (69.8)
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characteristics were compared using the χ2 test or Fisher
exact test (categorical variables) and the Student’s t test
(continuous variables). Gene–gene interactions were
assessed using the GMDR program (β version 0.7,
www.healthsystem.virginia.edu/internet/addiction-gen-
omics/Software) as previously reported [22, 23].
Significant independent predictors of AR were ana-
lyzed by logistic regression analysis. The relative risk of a
genotype with AR was expressed as odds ratio (OR) with
95% confidence interval (CI). The Cox proportional-
hazards model was used to describe the risk for primary
outcome and calculate the hazard ratio (HR) with
95% CI. The variables entered into the model were
the variables that differed significantly between the
AR + ASR group and AS group. All tests were two-
sided, and the threshold level of P < 0.05 indicated
statistical significance.
Results
Occurrence of AR in acute IS patients
Of the 850 patients taking aspirin, AR was detected in
175 (20.6%), ASR was detected in 45 (5.3%), and AS was
detected in 630 (74.1%). Diabetes mellitus, LDL-C and
fasting glucose levels and female gender were signifi-
cantly associated with ASR + AR in univariate analysis
(P = 0.02, Table 1).
Association of SNPs with AR
Genotype distributions for the 14 variants were in ac-
cordance with Hardy–Weinberg equilibrium (P > 0.05).
The frequency of TT + CT genotypes for rs1371097 was
significantly higher in the AR + ASR group than in AS
group (P = 0.01, Table 2). However, the single-locus ana-
lytical approach did not identify any differences in the
frequencies of other variant genotypes between the two
groups (all P > 0.05, Table 2).
Gene-gene interaction and its association with AR
We next used the GMDR method to investigate the as-
sociation of the 14 variants high-order interactions with
AR + ASR. With covariate adjustments, the best model
for AR + ASR was rs20417, rs1371097 and rs2317676,
which scored 10/10 for cross-validation consistency and
9/10 for the sign test (P = 0.016). The one-locus model
was computed for each variant and the prediction accur-
acy of these one-locus models was 0.5634, 0.5395 and
0.5237 (for rs20417, rs1371097, and rs2317676, respect-
ively), and a minimum P value was 0.9428. The signifi-
cance of this interaction was then confirmed using a
permutation test (P = 0.019), indicating that together
these three genetic variants significantly contribute to
ASR + AR. Further analysis demonstrated that, in
comparison to patients harboring wild-type genotype
rs20417GG, rs1371097CC, and rs2317676AA, the gene
interactions contributing most significantly to this model
were rs20417CC, rs1371097TT, and rs2317676GG;
rs20417CC, rs1371097TT, and rs2317676GG/AG;
rs20417CC, rs1371097CT, and rs2317676AG (Table 3).
These data demonstrated that interaction of the three
genetic variants contributed to ASR + AR in IS patients.
Risk factors for ASR + AR
The relative risk these three variants conferred was con-
sidered an interactive variable, with high-risk assigned as
one and low-risk assigned as zero. Logistic regression in-
dicated that high-risk interactive variables were signifi-
cant independent predictors of ASR + AR (OR = 2.35,
95% CI: 1.87–6.86, P = 0.002) after adjusting for other
covariates (Table 4).
Clinical outcome
Of the 850 patients enrolled, 121 (14.2%) developed
END, 17 (0.2%) had ERIS, 2 (0.2%) died, and 6 (0.7%)
had MI within 10 days of admission. The frequency of
END was higher in the AR + ASR group than that in AS
group (Table 5). However, the frequencies of ERIS, MI
and death did not differ significantly between the two
groups. Clinically, patients with END were older (70.8 ±
10.9 vs. 66.9 ± 11.7, P < 0.001), had higher glucose levels
at baseline (7.6 ± 2.2 vs. 6.3 ± 1.9, P < 0.001), and had a
higher prevalence of diabetes mellitus (54.5% [66/121]
vs. 17.1% [125/729], P < 0.001) compared with patients
without END. Furthermore, END was more common in
patients carrying high-risk interactive genotypes than
those with no such interactive genotypes (41.2% [61/148]
Table 3 Association between cerebral infarction and genotype combinations
rs20417 GG CC CC CC GC CC, GC CC CC, GC
rs1371097 CC TT TT CT CT TT TT, CT TT, CT
rs2317676 AA GG AG, GG AG AG GG GG GG, AG
OR 1 a 2.72 1.91 2.28 1.31 1.08 1.11 1.05
95% CI - 1.18-6.86 1.07–3.84 1.13–5.33 0.98–3.26 0.72–1.85 0.62–2.21 0.64–1.75
P value - 0.004 0.034 0.025 0.087 0.257 0.452 0.678
OR odds ratio
a The low-risk genotype for each genetic factor was used as the reference OR
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vs. 8.5% [60/702], P < 0.001). Cox regression analysis re-
vealed that high-risk interactive genotypes (HR: 2.47, 95%
CI, 1.42–7.8, P < 0.01), AR + ASR (HR: 2.04, 95% CI, 1.36–
6.25, P = 0.01), and high glucose level (HR: 1.56, 95% CI,
1.06–4.78, P = 0.03) were independent risk factors for
END (Table 6).
Effect of genotypes on platelet aggregation in both pre-
and post-aspirin treatment
Platelet aggregation did not differ significantly among
the 14 variants, or between the patients with and with-
out high-risk interactive genotypes at admission. Platelet
aggregation also did not differ among the 14 variants
post-aspirin treatment. However, after aspirin treatment
platelet aggregation was significantly higher in patients
carrying high-risk interactive genotypes than those with-
out high-risk interactive genotypes (P < 0.001, Table 7).
Discussion
In the present study, we used the GMDR approach to
investigate the potential contribution of fourteen vari-
ants in six genes to AR and END in 850 patients with
acute IS. We found that the prevalence of AR and ASR
was 20.6 and 5.3%, respectively, and that diabetes melli-
tus was associated with AR. These findings were in
accordance with previous studies [5, 18, 27]. Further,
aside from variant P2Y1 (rs1371097), we found no sig-
nificant differences in the distribution of the other vari-
ants between the AR + ASR group and AS group.
However, a high-risk interactive genotype, involving
rs20417, rs1371097, rs2317676, was independently asso-
ciated with AR and END.
The mechanisms underlying AR have not yet been
fully elucidated. Previous studies have suggested that AR
is correlated with gender, age, absorption or metabolic
dysfunction, drug compliance, drug interactions, dia-
betes mellitus, aspirin dose, cholesterol levels, and
inflammatory markers [28, 29]. Furthermore, the biosyn-
thesis of TXA2 and alternative pathways involved in
platelet activation, including ADP, collagen, epinephrine
and thrombin, have been implicated in AR [27, 30], sug-
gesting that multiple factors contribute to AR. Our re-
sults indicate that female gender, LDL-C, diabetes
mellitus and fasting glucose are significantly associated
with AR. Chronic hyperlipidemia plays a key role in
platelet activation both in vivo [31] and in vitro [32].
Davi et al. observed increased in vivo formation of 8-epi-
prostaglandin F2 alpha in chronic hyperlipidemia that
correlated with enhanced urine 11-dehydro-thromboxane
B2 production [33]. This may indicate an aspirin-
insensitive mechanism that links lipid peroxidation to
amplification of platelet activation. Diabetes mellitus or
high fasting glucose is associated with hyperlipidemia,
platelet dysfunction, chronic inflammation and endothelial
dysfunction, which impair aspirin responsiveness [34]. In
diabetic patients, other mechanisms that may be respon-
sible for reduced aspirin responsiveness include increased
calcium or esterase levels, circulating ADP, and platelet
turnover, P2Y12 receptor expression, upregulation of
other platelet activation pathways [35, 36]. Therefore, for
IS patients with diabetes or hyperlipidemia intensive anti-
platelet therapy may be important.
With the advances in next generation sequencing and
genetic association analysis, accumulating evidence has
suggested that genetic factors may be associated with
AR. COX and its receptors are involved in platelet acti-
vation and aggregation, and are inhibited by aspirin.
Polymorphisms in COX-2 rs20417 and COX-1 C50T
have been reported to be associated with impaired as-
pirin responsiveness [13, 14]. However, in both a previ-
ous study [18] and this study, these polymorphisms were
not found to be associated with AR in acute IS patients.
P2Y12 and P2Y1 are platelet membrane receptors and
Table 4 Logistic regression analysis of the significant
independent predictors of ASR + AR
Risk factor OR 95% CI P value
Female 0.86 0.69–1.34 0.232
Diabetes mellitus 2.02 1.14–4.23 0.023
High LDL-C 0.97 0.92–2.87 0.102
High blood glucose 1.02 0.93–3.42 0.086
Rs1371097TT/CT 0.92 0.84–2.34 0.124
High-risk interactive variable 2.35 1.87–6.86 0.002
AR aspirin resistance, ASR aspirin semi-resistance, OR odds ratio, CI confidence
intervals, LDL-C low-density lipoprotein cholesterol
Table 5 Association of aspirin resistance with clinical outcomes
AR + ASR AS P value
n = 220 n = 630
END (n, %) 69 (31.4) 52 (8.3) <0.001
ERIS (n, %) 5 (2.3) 12 (1.9) 0.74
MI (n, %) 2 (0.9) 4 (0.6) 0.83
Death (n, %) 0 (0.0) 2 (0.3) 0.82
AR aspirin resistance, ASR aspirin semi-resistance, AS aspirin sensitivity, END
early neurological deterioration, ERIS early recurrent ischemic stroke, MI
myocardial infarction
Table 6 Cox regression analysis of risk factors for END
Factor Hazard ratio 95% CI P value
Age 0.86 0.69–1.42 0.82
Diabetes mellitus 1.18 0.97–2.85 0.08
High fasting glucose 1.56 1.06–4.78 0.03
AR + ASR 2.04 1.36–6.25 0.01
High-risk interactive genotypes 2.47 1.42–7.84 <0.01
END early neurological deterioration, AR aspirin resistance, ASR aspirin
semi-resistance, CI confidence intervals
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Table 7 Effect of genotypes on platelet aggregation of both pre- and post-aspirin treatment (%)
Pre-aspirin aggregation Platelet Post-aspirin aggregation Platelet
AA- induced ADP-induced AA- induced ADP-induced
COX-1 (rs1236913)
CC (n = 765) 88.4 ± 15.7 89.2 ± 14.7 18.9 ± 9.2 66.8 ± 12.8
CT + TT (n = 85) 89.2 ± 14.6 89.7 ± 13.2 19.4 ± 8.8 67.5 ± 10.8
P-value 0.65 0.73 0.63 0.57
COX-1 (rs3842787)
CC (n = 675) 87.9 ± 16.3 88.6 ± 14.7 19.2 ± 8.4 67.7 ± 11.5
CT + TT (n = 175) 89.7 ± 13.6 90.1 ± 15.8 19.0 ± 7.8 66.6 ± 12.3
P-value 0.15 0.21 0.86 0.28
COX-2 (rs689466)
AA (n = 243) 88.9 ± 16.3 89.2 ± 12.8 20.1 ± 10.2 66.8 ± 13.2
AG + GG (n = 607) 89.7 ± 14.1 90.3 ± 16.9 18.9 ± 9.8 67.2 ± 11.5
P-value 0.51 0.36 0.12 0.67
COX-2 (rs20417)
GG (n = 583) 87.9 ± 15.4 88.3 ± 15.2 18.2 ± 8.6 65.9 ± 13.4
GC + CC (n = 267) 89.7 ± 15.7 89.6 ± 14.6 19.5 ± 9.6 67.1 ± 14.9
P-value 0.13 0.26 0.34 0.07
TXAS1 (rs194149)
GG (n = 265) 90.2 ± 16.7 89.4 ± 12.9 19.1 ± 7.6 67.9 ± 12.2
AG + AA (n = 585) 88.6 ± 17.5 88.9 ± 15.6 18.7 ± 6.7 68.4 ± 13.8
P-value 0.22 0.64 0.47 0.64
TXAS1 (rs2267679)
TT (n = 700) 88.9 ± 17.7 89.1 ± 14.9 19.3 ± 8.9 66.5 ± 14.2
CC + CT (n = 150) 90.3 ± 15.6 90.2 ± 16.4 18.4 ± 8.2 67.9 ± 15.5
P-value 0.33 0.44 0.19 0.31
TXAS1 (rs41708)
GG (n = 509) 88.8 ± 13.6 88.9 ± 15.2 18.8 ± 7.2 68.1 ± 12.5
TT + GT (n = 341) 90.1 ± 17.8 89.4 ± 13.8 19.3 ± 8.4 67.6 ± 11.1
P-value 0.18 0.63 0.41 0.54
P2Y1 (rs701265)
AA (n = 457) 88.9 ± 15.3 88.7 ± 16.1 19.2 ± 7.7 67.8 ± 13.2
AG + GG (n = 393) 89.6 ± 17.7 89.5 ± 14.2 18.4 ± 8.1 68.5 ± 14.4
P-value 0.54 0.42 0.15 0.44
P2Y1 (rs1439010)
AA (n = 460) 90.3 ± 16.8 90.1 ± 16.6 19.1 ± 6.8 66.9 ± 13.6
AG + GG (n = 390) 88.5 ± 15.2 89.0 ± 15.3 18.7 ± 7.4 67.7 ± 12.2
P-value 0.11 0.31 0.42 0.34
P2Y1 (rs1371097)
CC (n = 479) 89.2 ± 15.6 87.9 ± 16.2 18.8 ± 7.2 68.1 ± 12.5
TT + CT (n = 371) 88.6 ± 14.1 89.2 ± 15.6 19.3 ± 8.4 67.6 ± 11.1
P-value 0.57 0.21 0.31 0.62
P2Y12 (rs16863323)
CC (n = 206) 87.9 ± 16.4 88.8 ± 16.4 18.9 ± 7.6 67.2 ± 13.2
TT + CT (n = 644) 89.9 ± 18.7 89.2 ± 14.5 18.7 ± 8.2 67.8 ± 12.3
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play a key role in platelet aggregation, thrombosis and
the pharmacology of antiplatelet therapy [9]. Grinshtein
et al.[17] reported that AR was associated with P2Y12
and P2Y1 polymorphisms; but Goodman et al.[15] did
not find these polymorphisms to be associated with AR.
The GPllb/llla receptor is a major regulator of platelet
aggregation. GPllb/llla bind fibrinogen and cross-link
adjacent platelets. Some studies have suggested that
GPllb/llla variants are associated with AR [15, 37],
whereas other studies have not found such association
[38]. This lack of consistency in the literature makes it
difficult to define the effects of these gene variants on
aspirin responsiveness. The potential reasons for the
conflicting results may include divergent ethnicity-
specific genetic profiles, population stratification, sample
sizes [39]. These controversial results may also reflect
the complexity of mechanisms by which genetic factors
contribute to AR. Therefore, it may be crucial to analyze
the effects of gene-gene interactions on AR risk. In this
study, GMDR analysis found that a high-risk interactive
genotype, involving rs20417, rs1371097, rs2317676, was
associated with AR and END. The mechanism by which
the three variants interact is unclear. The three genes
encode COX enzymes and platelet activation and aggre-
gation receptors which modulate aspirin pharmaco-
dynamics and pharmacokinetics, a principal component
of the aspirin response. Our results demonstrated that
AA or ADP induced significantly more platelet aggrega-
tion in patients carrying high-risk interactive genotypes
than those without these genotypes. We speculate that
the interaction of rs20417, rs1371097 and rs2317676
could potentially cause high platelet aggregation in these
individuals, thus increasing risk of AR and END. How-
ever, further studies will be required to investigate the
mechanisms by which these gene interactions impair as-
pirin responsiveness.
In this study, the frequency of END was 14.2%, and
high-risk interactive genotypes and AR were independ-
ently associated with END. While the mechanisms
underpinning END have not been fully understood.
Thrombosis is one of the causes of ischemic stroke, and
platelet activation plays a key role in thrombosis [40], IS
and END pathogenesis [26, 41]. AR and high-risk inter-
active genotypes may reduce inhibition of platelet activa-
tion [7], leading to END. Thus, for IS patients with AR
or high-risk interactive genotypes antiplatelet therapy
may be important.
Recurrent ischemic stroke is common in IS patients. In
this study, the frequencies of ERIS, MI and death did not
significantly differ between the AR +ASR group and AS
group. Furthermore, we found that high-risk interactive
genotypes did not increase the risk of recurrent stroke.
Our conclusions are limited by the scope of this
particular study. Firstly, we enrolled a relatively small
sample size, including only two centers, and the follow
up period was relatively short. Our findings will need be
validated in larger, multi-center studies that follow
patients for longer. Secondly, although we genotyped
multiple functional variants in known aspirin-relevant
genes, some rare functional variants may have been
overlooked; thus, we are not able to exclude the role of
other polymorphisms in the regulation of AR. Finally,
although the main aim of this study was to assess the oc-
currence of AR, and the association of genetic variants
Table 7 Effect of genotypes on platelet aggregation of both pre- and post-aspirin treatment (%) (Continued)
P-value 0.14 0.76 0.73 0.51
P2Y12 (rs9859538)
GG (n = 626) 88.5 ± 16.5 88.9 ± 14.3 18.4 ± 8.7 66.7 ± 11.
AG + AA (n = 224) 89.9 ± 16.8 90.1 ± 16.7 19.1 ± 7.9 67.5 ± 13.6
P-value 0.28 0.31 0.33 0.41
GPIIIa (rs2317676)
AA (n = 536) 89.5 ± 15.2 87.9 ± 13.7 19.2 ± 8.2 68.3 ± 14.2
AG + GG (n = 314) 88.2 ± 15.7 89.4 ± 17.8 18.5 ± 7.1 67.4 ± 13.3
P-value 0.32 0.23 0.26 0.36
GPIIIa (rs11871251)
AA (n = 267) 89.2 ± 12.6 89.8 ± 16.6 19.4 ± 8.7 66.9 ± 15.7
AG + GG (n = 583) 88.6 ± 14.9 89.2 ± 14.3 18.6 ± 7.5 67.5 ± 14.4
P-value 0.53 0.56 0.19 0.49
High-risk interactive genotypes
Yes (n = 147) 90.6 ± 18.4 90.3 ± 17.5 30.3 ± 9.2 79.9 ± 12.2
No (n = 703) 88.8 ± 16.7 88.7 ± 13.8 15.6 ± 6.8 62.3 ± 11.1
P-value 0.28 0.27 < 0.001 < 0.001
Yi et al. BMC Neurology  (2017) 17:4 Page 7 of 9
with AR and early clinical outcomes in acute ischemic
stroke, we did not include the relevant negative control to
allow the association of these gene variants with ischemic
stroke to be analyzes. We therefore could not eliminate the
possibility that these gene variants interact to contribute to
acute stroke themselves. Thus, it will be essential to in-
clude a non-stroke group taking aspirin in future studies.
Conclusion
We assessed the contribution of fourteen variants
from six genes with AR and END in acute IS patients
using the GMDR approach. We found that combina-
tions of rs20417CC, rs1371097TT, and rs2317676GG;
rs20417CC, rs1371097TT, and rs2317676GG/AG;
rs20417CC, rs1371097CT, and rs2317676AG were associ-
ated with a higher risk of AR in IS patients. Moreover, AR
and high-risk interactive genotypes were independently
associated with END. Our findings suggest that the gen-
etic basis for AR is complex, and that genotyping of mul-
tiple relevant genes may be necessary to predict AR risk
and manage IS patients.
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